Teva Beats Q1 2026 Forecasts as AUSTEDO & UZEDY Surge — Acquires Emalex for $700M Tourette Drug
Teva buys Emalex for $700M to add a new Tourette drug. Strong sales growth led by key medicines; generics weaker but outlook solid.
/ 17 items
#XY Earnings Movers↓
Humana Beats Q1 2026 Earnings Expectations, Reaffirms Full-Year Adjusted Profit Guidance
Humana beat Q1 2026 expectations, revenue rose, Medicare membership grew, outlook steady but GAAP cut due to lower ratings.
UnitedHealth Group Beats Q1 2026 Expectations and Raises Full-Year Profit Outlook
UnitedHealth Group beat expectations, raised outlook, cut costs, and grew steadily—showing a solid turnaround and boosting investor confidence.
Abbott Beats Q1 Profit and Revenue Estimates, But Cuts 2026 Outlook After $23B Exact Sciences Deal
Abbott beat Q1 earnings, boosted by cancer diagnostics deal, but cut 2026 profit outlook due to acquisition costs.
Weight Watchers Beats 2025 Guidance as GLP-1 Clinical Subscribers Jump 42%
WW International reported Q4 and full-year 2025 results beating guidance, with strong growth in clinical subscribers thanks to GLP-1 integration.